Alpha Cognition Inc. has announced its financial results for the second quarter ending June 30, 2025. The company reported ZUNVEYL net product revenues of $1.6 million for the quarter, contributing to approximately $2 million in net product revenues year-to-date. The net operating loss for the three months ended June 30, 2025, was $5.7 million, an increase from $2.4 million for the same period in 2024. The net loss for the quarter was $10.5 million, up from $2.1 million in the same period of the previous year, primarily due to a $5.2 million non-cash change in the value of warrant liabilities. Research and development expenses decreased to $317 thousand for the three months ended June 30, 2025, from $967 thousand in the same period of 2024. Selling, general, and administrative expenses rose to $6.5 million from $1.4 million in the same period of the prior year, driven primarily by commercial-readiness activities. The company also highlighted key operational achievements, including the successful completion of the first quarter of ZUNVEYL commercialization and securing its first national Medicare Part D contract with no prior authorization required. Additionally, the Bomb Blast Study concluded, demonstrating that ALPHA-1062 reduced neuroinflammation and neuropathology associated with blast trauma. The company maintains a strong balance sheet with cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate.